166 related articles for article (PubMed ID: 29783721)
1. AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations.
Meng X; Bi J; Li Y; Yang S; Zhang Y; Li M; Liu H; Li Y; Mcdonald ME; Thiel KW; Wen KK; Wang X; Wu M; Leslie KK
Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29783721
[TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
3. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
Seo HR; Nam AR; Bang JH; Oh KS; Kim JM; Yoon J; Kim TY; Oh DY
Cancer Res Treat; 2022 Apr; 54(2):541-553. PubMed ID: 34352995
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
6. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
[TBL] [Abstract][Full Text] [Related]
7. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
[TBL] [Abstract][Full Text] [Related]
8. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
9. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
Geenen JJJ; Schellens JHM
Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
[TBL] [Abstract][Full Text] [Related]
11. Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.
Serpico AF; D'Alterio G; Vetrei C; Della Monica R; Nardella L; Visconti R; Grieco D
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31200459
[TBL] [Abstract][Full Text] [Related]
12. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
13. Mutational status of
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2017 Sep; 8(40):67526-67537. PubMed ID: 28978051
[No Abstract] [Full Text] [Related]
14. Development and Characterization of a Wee1 Kinase Degrader.
Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
Leijen S; Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):186-91. PubMed ID: 20406171
[TBL] [Abstract][Full Text] [Related]
16. AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells.
Webster PJ; Littlejohns AT; Gaunt HJ; Prasad KR; Beech DJ; Burke DA
Cell Cycle; 2017; 16(22):2176-2182. PubMed ID: 28296564
[TBL] [Abstract][Full Text] [Related]
17. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.
Patel P; Sun L; Robbins Y; Clavijo PE; Friedman J; Silvin C; Van Waes C; Cook J; Mitchell J; Allen C
Oncoimmunology; 2019; 8(11):e1638207. PubMed ID: 31646086
[TBL] [Abstract][Full Text] [Related]
18. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
[TBL] [Abstract][Full Text] [Related]
19. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
Hartman SJ; Bagby SM; Yacob BW; Simmons DM; MacBeth M; Lieu CH; Davis SL; Leal AD; Tentler JJ; Diamond JR; Eckhardt SG; Messersmith WA; Pitts TM
Front Oncol; 2021; 11():642328. PubMed ID: 33869031
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations.
Meng X; Gao JZ; Gomendoza SMT; Li JW; Yang S
Front Med (Lausanne); 2021; 8():737951. PubMed ID: 34671620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
